Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer
Phase III Randomized Trial Comparing Total Androgen Blockade Versus Total Androgen Blockade Plus Pelvic Irradiation in Clinical Stage T3-4, N0, M0 Adenocarcinoma of the Prostate
Sponsor: Eastern Cooperative Oncology Group
Listed as NCT00002633, this PHASE3 trial focuses on Prostate Cancer and remains completed. Sponsored by Eastern Cooperative Oncology Group, it has been updated 9 times since 1995, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
May 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — May 2023 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
May 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — May 2020 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Feb 1995
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eastern Cooperative Oncology Group
- Medical Research Council
- NCIC Clinical Trials Group
- National Cancer Institute (NCI)
- SWOG Cancer Research Network
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Edmonton, Canada , Greater Sudbury, Canada , Halifax, Canada , Hamilton, Canada , Kingston, Canada , London, Canada , Montreal, Canada , Ottawa, Canada , Saskatoon, Canada , Surrey, Canada and 4 more locations